|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
35,720,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile HCW Biologics is a biopharmaceutical company focused on discovering and developing immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. Co. has selected two molecules as its primary product candidates: HCW9218 and HCW9302. HCW9218 is designed to treat the impact of accumulated senescent cells and the Senescence-Associated Secretory Phenotype (SASP) factors which they secrete by eliminating senescent cells and reducing SASP factors. HCW9302 is designed to activate and expand regulatory T cells to suppress the activity of inflammasome-bearing cells and the inflammatory factors which they secrete.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
108,208 |
500,616 |
Total Buy Value |
$0 |
$0 |
$218,516 |
$1,091,132 |
Total People Bought |
0 |
0 |
4 |
4 |
Total Buy Transactions |
0 |
0 |
19 |
52 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Wong Hing C |
Chief Executive Officer |
|
2024-02-20 |
4 |
A |
$1.40 |
$1,035,003 |
D/D |
739,288 |
16,054,156 |
|
- |
|
Greene Rick S. |
Director |
|
2024-02-20 |
4 |
A |
$1.40 |
$50,000 |
D/D |
35,714 |
44,125 |
|
- |
|
Garrett Scott T |
Director |
|
2024-02-20 |
4 |
A |
$1.40 |
$200,001 |
I/I |
142,858 |
267,858 |
|
- |
|
Giles Lisa M. |
Director |
|
2024-02-20 |
4 |
A |
$1.40 |
$50,001 |
D/D |
35,715 |
35,815 |
|
- |
|
Byam Rebecca |
Chief Financial Officer |
|
2024-02-20 |
4 |
A |
$1.40 |
$1,065,000 |
D/D |
760,714 |
1,381,909 |
|
- |
|
Flowers Lee |
SVP of Business Development |
|
2024-02-20 |
4 |
A |
$1.40 |
$100,001 |
D/D |
71,429 |
190,238 |
|
- |
|
Rhode Peter |
See Remarks |
|
2023-12-11 |
4 |
OE |
$0.14 |
$1,960 |
D/D |
14,000 |
77,500 |
|
- |
|
Flowers Lee |
SVP of Business Development |
|
2023-12-08 |
4 |
OE |
$0.14 |
$1,050 |
D/D |
7,501 |
118,809 |
|
- |
|
Rhode Peter |
See Remarks |
|
2023-11-17 |
4 |
OE |
$0.14 |
$2,100 |
D/D |
15,000 |
63,500 |
|
- |
|
Byam Rebecca |
Chief Financial Officer |
|
2023-10-19 |
4 |
OE |
$0.14 |
$6,615 |
D/D |
47,249 |
621,195 |
|
- |
|
Wong Hing C |
Chief Executive Officer |
|
2023-09-14 |
4 |
B |
$2.08 |
$3,741 |
D/D |
1,800 |
15,314,868 |
2.73 |
- |
|
Winer Gary M |
Director |
|
2023-09-14 |
4 |
B |
$2.05 |
$2,139 |
D/D |
1,041 |
17,000 |
2.31 |
- |
|
Byam Rebecca |
Chief Financial Officer |
|
2023-09-13 |
4 |
B |
$2.10 |
$10,490 |
D/D |
5,000 |
573,946 |
2.74 |
- |
|
Winer Gary M |
Director |
|
2023-09-13 |
4 |
B |
$2.00 |
$1,117 |
D/D |
546 |
15,959 |
2.31 |
- |
|
Byam Rebecca |
Chief Financial Officer |
|
2023-09-12 |
4 |
B |
$2.09 |
$10,442 |
D/D |
5,000 |
568,946 |
2.74 |
- |
|
Winer Gary M |
Director |
|
2023-09-12 |
4 |
B |
$2.05 |
$1,025 |
D/D |
500 |
15,413 |
2.31 |
- |
|
Byam Rebecca |
Chief Financial Officer |
|
2023-09-11 |
4 |
B |
$2.05 |
$10,273 |
D/D |
5,000 |
563,946 |
2.74 |
- |
|
Winer Gary M |
Director |
|
2023-09-11 |
4 |
B |
$2.05 |
$203 |
D/D |
99 |
14,913 |
2.31 |
- |
|
Winer Gary M |
Director |
|
2023-09-08 |
4 |
B |
$1.90 |
$2 |
D/D |
1 |
14,814 |
2.31 |
- |
|
Byam Rebecca |
Chief Financial Officer |
|
2023-09-08 |
4 |
B |
$2.02 |
$10,111 |
D/D |
5,000 |
558,946 |
2.74 |
- |
|
Byam Rebecca |
Chief Financial Officer |
|
2023-09-07 |
4 |
B |
$1.95 |
$9,742 |
D/D |
5,000 |
553,946 |
2.74 |
- |
|
Winer Gary M |
Director |
|
2023-09-07 |
4 |
B |
$1.95 |
$123 |
D/D |
63 |
14,813 |
2.31 |
- |
|
Byam Rebecca |
Chief Financial Officer |
|
2023-09-06 |
4 |
B |
$1.95 |
$9,749 |
D/D |
5,000 |
548,946 |
2.74 |
- |
|
Winer Gary M |
Director |
|
2023-09-05 |
4 |
B |
$1.75 |
$700 |
D/D |
400 |
14,750 |
2.31 |
- |
|
Byam Rebecca |
Chief Financial Officer |
|
2023-06-09 |
4 |
B |
$2.06 |
$41,286 |
D/D |
20,000 |
543,946 |
2.74 |
- |
|
91 Records found
|
|
Page 1 of 4 |
|
|